Dallas, TX
Ketamine Therapy clinics in Dallas
Dallas has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. Texas requires an in person evaluation for Schedule III telehealth prescribing under current DEA rules; most ketamine in Texas is delivered in clinic. Most Dallas clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Dallas only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Dallas, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Dallas sits in the standard range: single IV infusions run 500 to 900 dollars, a full 6 session protocol lands at 3,000 to 5,400, and Spravato copays depend on insurance coverage. A reputable Dallas ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Zoe Psychiatry & Sleep Medicine
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Sleep Apnea Treatment
Peak Life Health
- PRP Therapy
- Ketamine Therapy
- Arthritis Treatment
- Erectile Dysfunction (ED) Treatment
- Hormone Replacement Therapy (HRT)
Regulatory context
A note on Texas's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
HB 1802 / Psilocybin and MDMA Research (2021)
Required Texas Health and Human Services Commission to study psilocybin and MDMA for PTSD treatment in veterans; report completed. -
Texas Ibogaine Initiative (HB 3717, 2025 pending)
Would allocate $50 million for FDA-regulated ibogaine clinical trials, potentially the largest state psychedelic research investment in US history. -
Texas Controlled Substances Act
Mirrors federal scheduling.
Texas enforces federal scheduling. The Texas Medical Board oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. Texas PMP requires controlled substance reporting. Texas has seen rapid ketamine clinic growth in Austin, Dallas, and Houston markets with corresponding enforcement attention on compounding and telehealth practices.